Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia

Clin Microbiol Infect. 2023 Jun;29(6):673-675. doi: 10.1016/j.cmi.2023.02.020. Epub 2023 Mar 3.

Authors

Ryan C Maves¹, Andre C Kalil²

Affiliations

¹ Section of Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Electronic address: rmaves@wakehealth.edu.
² Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

PMID: 36870434
DOI: 10.1016/j.cmi.2023.02.020

No abstract available

Keywords: Clinical trials; Clostridioides difficile; Community-acquired pneumonia; Doxycycline; Microbiome; Pneumonia; Tetracyclines.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Ceftriaxone / therapeutic use
Community-Acquired Infections* / drug therapy
Community-Acquired Infections* / microbiology
Doxycycline / therapeutic use
Drug Therapy, Combination
Humans
Pneumonia* / drug therapy

Substances

Ceftriaxone
Doxycycline
Anti-Bacterial Agents